ALLERGY THERAPEUTICS PLC Logo

ALLERGY THERAPEUTICS PLC

Develops innovative, aluminum-free allergy immunotherapy vaccines for the European market.

AGY | IL

Overview

Corporate Details

ISIN(s):
GB00B02LCQ05
LEI:
213800PQ7AHK7KGVOE23
Country:
United Kingdom
Address:
DOMINION WAY, BN14 8SA WORTHING
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Allergy Therapeutics PLC is an international, commercial-stage biotechnology company focused on the treatment and diagnosis of allergic disorders. Leveraging its specialist expertise in immunology, the company researches and develops a portfolio of convenient allergy immunotherapy (AIT) products. A key area of focus is its innovative, aluminum-free vaccines that have the potential to modify or cure allergic diseases. The company markets its products primarily across Europe, aiming to transform the lives of patients by providing effective and convenient treatments for various allergies.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-06 09:40
Regulatory News Service
Company to Evaluate Dual Listing on HKEX
English 11.2 KB
2025-10-30 08:00
Regulatory News Service
G308 Phase III Year 2 Patient Screening Starts
English 15.4 KB
2025-10-29 08:00
Share Issue/Capital Change
Warrant Exercise and Paydown of Debt
English 42.4 KB
2025-10-16 08:00
Regulatory News Service
Further progress in Phase I/IIa PROTECT trial
English 18.4 KB
2025-07-31 08:00
Report Publication Announcement
Grass MATA MPL Publications in Allergy Journal
English 19.2 KB
2025-07-21 08:00
Business and Financial Review
Trading update for the year ended 30 June 2025
English 19.9 KB
2025-07-11 08:00
Share Issue/Capital Change
PDMR Dealings
English 38.3 KB
2025-03-31 08:00
Interim Report
Interim Results for six months ended 31 Dec 2024
English 211.9 KB
2025-03-27 08:00
Legal Proceedings Report
Advancement to final phase of PROTECT trial
English 16.8 KB
2025-03-03 08:00
Remuneration Information
New Executive Long Term Incentive Awards
English 42.9 KB
2025-02-27 08:00
Regulatory News Service
Presentations at 2025 AAAAI / WAO Joint Congress
English 15.9 KB
2025-02-17 08:00
Environmental & Social Information
Grass MATA MPL Phase III data published in Allergy
English 17.1 KB
2025-02-14 08:00
Remuneration Information
Grant of Options
English 36.4 KB
2025-01-28 08:00
Earnings Release
Half Year Trading update
English 15.6 KB
2025-01-22 08:00
Share Issue/Capital Change
PDMR Dealing and Total Voting Rights
English 28.0 KB

Automate Your Workflow. Get a real-time feed of all ALLERGY THERAPEUTICS PLC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for ALLERGY THERAPEUTICS PLC

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for ALLERGY THERAPEUTICS PLC via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
NuCana plc Logo
Develops safer anti-cancer medicines with ProTide technology to overcome cell resistance.
United States of America NCNA
NUFORMIX PLC Logo
Repurposing drugs for fibrosis and oncology using proprietary cocrystal technology.
United Kingdom NFX
Nurix Therapeutics, Inc. Logo
Developing protein degradation medicines to treat cancer and autoimmune diseases.
United States of America NRIX
NUTEX Investments Plc Logo
Develops & distributes health, cosmetic & pharma products from natural ingredients globally.
Hungary NUTEX
NutriBand Inc. Logo
Develops abuse-deterrent transdermal patches to make potent drug delivery safer.
United States of America NTRB
Nuvalent, Inc. Logo
Designs targeted small molecule drugs for kinase-driven cancers to overcome treatment resistance.
United States of America NUVL
Nuvation Bio Inc. Logo
A clinical-stage biopharma developing novel drugs for difficult-to-treat cancers.
United States of America NUVB
Nxera Pharma Co., Ltd. Logo
Biopharma using SBDD tech to develop medicines for neurology and gastroenterology.
Japan 4565
ObsEva SA Logo
Developed novel therapeutics for women's reproductive health and pregnancy.
Switzerland OBSN
OCULAR THERAPEUTIX, INC Logo
Develops hydrogel drug delivery therapies for eye diseases like wet AMD and glaucoma.
United States of America OCUL

Talk to a Data Expert

Have a question? We'll get back to you promptly.